The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Asthma and COPD Market Research Report 2025
Synopsis
Drugs used as treatments for asthma and COPD
The global Drugs for Asthma and COPD market was valued at US$ 45700 million in 2023 and is anticipated to reach US$ 68020 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The market for drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) is expected to witness substantial growth in the coming years. The increasing prevalence of these respiratory disorders, growing awareness about their diagnosis and management, and advancements in drug therapies are key drivers of market expansion. Bronchodilators and corticosteroids are commonly prescribed medications for asthma and COPD, and the market for these drugs is highly competitive, with several pharmaceutical companies involved in their production and distribution. However, challenges such as high treatment costs, side effects, and the availability of generic alternatives may hinder market growth. Nonetheless, the drugs for asthma and COPD market holds significant opportunities for growth, driven by the rising global burden of these respiratory conditions and the continuous development of novel therapeutic options.
This report aims to provide a comprehensive presentation of the global market for Drugs for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Asthma and COPD.
Report Scope
The Drugs for Asthma and COPD market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Asthma and COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Asthma and COPD companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
AstraZeneca
Boehringer Ingelheim
Vertex
Roche
Novartis
Teva
Chiesi
Mylan
Sumitomo Dainippon
Merck
Beximco
Segment by Type
Inhalable & Nasal Spray
Oral
Others
Segment by Application
Asthma
COPD
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Asthma and COPD companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Drugs used as treatments for asthma and COPD
The global Drugs for Asthma and COPD market was valued at US$ 45700 million in 2023 and is anticipated to reach US$ 68020 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The market for drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) is expected to witness substantial growth in the coming years. The increasing prevalence of these respiratory disorders, growing awareness about their diagnosis and management, and advancements in drug therapies are key drivers of market expansion. Bronchodilators and corticosteroids are commonly prescribed medications for asthma and COPD, and the market for these drugs is highly competitive, with several pharmaceutical companies involved in their production and distribution. However, challenges such as high treatment costs, side effects, and the availability of generic alternatives may hinder market growth. Nonetheless, the drugs for asthma and COPD market holds significant opportunities for growth, driven by the rising global burden of these respiratory conditions and the continuous development of novel therapeutic options.
This report aims to provide a comprehensive presentation of the global market for Drugs for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Asthma and COPD.
Report Scope
The Drugs for Asthma and COPD market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Asthma and COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Asthma and COPD companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
AstraZeneca
Boehringer Ingelheim
Vertex
Roche
Novartis
Teva
Chiesi
Mylan
Sumitomo Dainippon
Merck
Beximco
Segment by Type
Inhalable & Nasal Spray
Oral
Others
Segment by Application
Asthma
COPD
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Asthma and COPD companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Asthma and COPD Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Inhalable & Nasal Spray
1.2.3 Oral
1.2.4 Others
1.3 Market by Application
1.3.1 Global Drugs for Asthma and COPD Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Asthma
1.3.3 COPD
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Asthma and COPD Market Perspective (2019-2030)
2.2 Drugs for Asthma and COPD Growth Trends by Region
2.2.1 Global Drugs for Asthma and COPD Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Asthma and COPD Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Asthma and COPD Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Asthma and COPD Market Dynamics
2.3.1 Drugs for Asthma and COPD Industry Trends
2.3.2 Drugs for Asthma and COPD Market Drivers
2.3.3 Drugs for Asthma and COPD Market Challenges
2.3.4 Drugs for Asthma and COPD Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Asthma and COPD Players by Revenue
3.1.1 Global Top Drugs for Asthma and COPD Players by Revenue (2019-2024)
3.1.2 Global Drugs for Asthma and COPD Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Asthma and COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Asthma and COPD Revenue
3.4 Global Drugs for Asthma and COPD Market Concentration Ratio
3.4.1 Global Drugs for Asthma and COPD Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Asthma and COPD Revenue in 2023
3.5 Drugs for Asthma and COPD Key Players Head office and Area Served
3.6 Key Players Drugs for Asthma and COPD Product Solution and Service
3.7 Date of Enter into Drugs for Asthma and COPD Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Asthma and COPD Breakdown Data by Type
4.1 Global Drugs for Asthma and COPD Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Asthma and COPD Forecasted Market Size by Type (2025-2030)
5 Drugs for Asthma and COPD Breakdown Data by Application
5.1 Global Drugs for Asthma and COPD Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Asthma and COPD Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Asthma and COPD Market Size (2019-2030)
6.2 North America Drugs for Asthma and COPD Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Asthma and COPD Market Size by Country (2019-2024)
6.4 North America Drugs for Asthma and COPD Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Asthma and COPD Market Size (2019-2030)
7.2 Europe Drugs for Asthma and COPD Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Asthma and COPD Market Size by Country (2019-2024)
7.4 Europe Drugs for Asthma and COPD Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Asthma and COPD Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Asthma and COPD Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Asthma and COPD Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Asthma and COPD Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Asthma and COPD Market Size (2019-2030)
9.2 Latin America Drugs for Asthma and COPD Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Asthma and COPD Market Size by Country (2019-2024)
9.4 Latin America Drugs for Asthma and COPD Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Asthma and COPD Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Asthma and COPD Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Asthma and COPD Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Asthma and COPD Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Drugs for Asthma and COPD Introduction
11.1.4 GSK Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.1.5 GSK Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Drugs for Asthma and COPD Introduction
11.2.4 AstraZeneca Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.2.5 AstraZeneca Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Drugs for Asthma and COPD Introduction
11.3.4 Boehringer Ingelheim Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Drugs for Asthma and COPD Introduction
11.4.4 Vertex Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.4.5 Vertex Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Drugs for Asthma and COPD Introduction
11.5.4 Roche Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Drugs for Asthma and COPD Introduction
11.6.4 Novartis Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Teva
11.7.1 Teva Company Detail
11.7.2 Teva Business Overview
11.7.3 Teva Drugs for Asthma and COPD Introduction
11.7.4 Teva Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.7.5 Teva Recent Development
11.8 Chiesi
11.8.1 Chiesi Company Detail
11.8.2 Chiesi Business Overview
11.8.3 Chiesi Drugs for Asthma and COPD Introduction
11.8.4 Chiesi Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.8.5 Chiesi Recent Development
11.9 Mylan
11.9.1 Mylan Company Detail
11.9.2 Mylan Business Overview
11.9.3 Mylan Drugs for Asthma and COPD Introduction
11.9.4 Mylan Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.9.5 Mylan Recent Development
11.10 Sumitomo Dainippon
11.10.1 Sumitomo Dainippon Company Detail
11.10.2 Sumitomo Dainippon Business Overview
11.10.3 Sumitomo Dainippon Drugs for Asthma and COPD Introduction
11.10.4 Sumitomo Dainippon Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.10.5 Sumitomo Dainippon Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Drugs for Asthma and COPD Introduction
11.11.4 Merck Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.11.5 Merck Recent Development
11.12 Beximco
11.12.1 Beximco Company Detail
11.12.2 Beximco Business Overview
11.12.3 Beximco Drugs for Asthma and COPD Introduction
11.12.4 Beximco Revenue in Drugs for Asthma and COPD Business (2019-2024)
11.12.5 Beximco Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
